Purity>95% (SDS-PAGE&SEC); Endotoxin Level<1.0EU/mg; Human IgG1; CHO; ELISA, FACS, Functional assay, Animal Model; Unconjugated
| SKU | Size | Availability | Price | Qty |
|---|---|---|---|---|
| Ab175533-100μg | 100μg | Available within 8-12 weeks(?) Production requires sourcing of materials. We appreciate your patience and understanding. | $79.90 | |
| Ab175533-1mg | 1mg | Available within 8-12 weeks(?) Production requires sourcing of materials. We appreciate your patience and understanding. | $379.90 | |
| Ab175533-5mg | 5mg | In stock | $979.90 | |
| Ab175533-10mg | 10mg | Available within 8-12 weeks(?) Production requires sourcing of materials. We appreciate your patience and understanding. | $1,799.90 |
Purity>95% (SDS-PAGE&SEC); Endotoxin Level<1.0EU/mg; Human IgG1; CHO; ELISA, FACS, Functional assay, Animal Model; Unconjugated
| Product Name | Etaracizumab (anti-Integrin aVb3) - Primary antibody, specific to Integrin aVb3 (ITGAV & ITGB3), >95%, high purity, Human IgG1 |
|---|---|
| Synonyms | antigen identified by monoclonal antibody L230 antibody; CD 51 antibody; CD51 antibody; DKFZp686A08142 antibody; Integrin alpha five antibody; integrin alpha V beta 3 antibody; Integrin alpha-5 antibody; integrin alpha-V antibody; Integrin alpha-V light c |
| Specifications & Purity | ExactAb™, Validated, Carrier Free, Low Endotoxin, Azide Free, Recombinant, ≥95%(SDS-PAGE&SEC), Lot by Lot |
| Specificity | Integrin aVb3 (ITGAV & ITGB3) |
| Conjugation | Unconjugated |
| Grade | Azide Free, Carrier Free, ExactAb™, Low Endotoxin, Recombinant, Validated |
| Action Type | ANTAGONIST |
| Mechanism of action | Antibody of integrin αVβ3 |
| Product Description | Etaracizumab (anti-Integrin aVb3) is an αvβ3 integrin IgG1 monoclonal antibody. Etaracizumab (anti-Integrin aVb3) inhibits angiogenesis and melanoma tumor growth. Etaracizumab (anti-Integrin aVb3) can be used to research anticancer. |
| Isotype | Human IgG1 |
|---|---|
| Light Chain Type | kappa |
| SDS-PAGE | 26.2 kDa (Light Chain) & 51.4 kDa (Heavy Chain), under reducing conditions; 185.3 kDa, under non-reducing conditions. |
| Purification Method | Protein A purified |
| Purity | >95% |
| Form | Liquid |
| Concentration | Lot by Lot |
| Storage Temp | Store at -80°C,Avoid repeated freezing and thawing |
| Shipped In | Ice chest + Ice pads |
| Stability And Storage | Store at -80℃ for 24 months. Upon delivery aliquot. Avoid freeze/thaw cycle. |
| CAS | 892553-42-3 |
Etaracizumab (anti-Integrin aVb3) (Ab175533) - Flow Cytometry
Flow Cytometry analysis of HUVEC cells labelling Integrin aVb3 (red) with Etaracizumab (anti-Integrin aVb3) (Ab175533). Goat Anti-Human IgG (PE) (Ab175838) at a dilution of 1/1000 was used as the secondary antibody. Blue - Isotype control, human IgG (Ab170213). Black - Unlabelled control, cells without incubation with primary antibody.
Etaracizumab (anti-Integrin aVb3) (Ab175533) - SEC
The purity of Etaracizumab (anti-Integrin aVb3) (Ab175533) is more than 95% verified by HPLC.
| Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
|---|
| Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
|---|
| Wikipedia | Etaracizumab |
|---|---|
| IMGT/mAb-DB | 240 |
Enter Lot Number to search for COA:
To view the certificate results,please click on a Lot number.For Lot numbers from past orders,please use our order status section
| Lot Number | Certificate Type | Date | Item |
|---|---|---|---|
 ZJ24F0303915 | Certificate of Analysis | Mar 29, 2024 | Ab175533 |
| ZJ24F0303914 | Certificate of Analysis | Mar 29, 2024 | Ab175533 |
| ZJ24F0303913 | Certificate of Analysis | Mar 29, 2024 | Ab175533 |
| 1. Mulgrew K, Kinneer K, Yao XT, Ward BK, Damschroder MM, Walsh B, Mao SY, Gao C, Kiener PA, Coats S et al.. (2006) Direct targeting of alphavbeta3 integrin on tumor cells with a monoclonal antibody, Abegrin.. Mol Cancer Ther, 5 (12): (3122-9). [PMID:17172415] |
| 2. Delbaldo C, Raymond E, Vera K, Hammershaimb L, Kaucic K, Lozahic S, Marty M, Faivre S. (2008) Phase I and pharmacokinetic study of etaracizumab (Abegrin), a humanized monoclonal antibody against alphavbeta3 integrin receptor, in patients with advanced solid tumors.. Invest New Drugs, 26 (1): (35-43). [PMID:17876527] |
| 3. Felding-Habermann B, Cheresh DA. (1993) Vitronectin and its receptors.. Curr Opin Cell Biol, 5 (5): (864-8). [PMID:7694604] |
